2252 GMT - Jefferies pares its price target on pharmaceutical company CSL by 9.8% to A$212.00/share after assuming slower growth in immunoglobulin and albumin. Analyst David Stanton says investors' near-term focus is on CSL's performance in immunoglobulin in the U.S. and in albumin in China. Both markets appear underpenetrated, Jefferies says. So, the industry should grow over the medium term. "That said, industry feedback suggests that, at present, 2H industry growth rates in these markets are not stellar, throwing in question CSL's 'strong 2H ambition'," Jefferies says. Its EPS forecast for FY 2026 falls by around 2%, and for FY 2027 by some 5%. CSL ended last week at A$139.19. (david.winning@wsj.com; @dwinningWSJ)

(END) Dow Jones Newswires

April 12, 2026 18:52 ET (22:52 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.